Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma

2022/02/09 by Tomoki Makino, Makoto Yamasaki, Koji Tanaka +17 · 16 citations
Medicine · #Chemotherapy #Cisplatin #Clinical endpoint #Clinical trial #Colorectal and Anal Carcinomas #Confidence interval #Docetaxel #Esophageal Cancer Research and Treatment #Fluorouracil #Hazard ratio #Head and Neck Cancer Studies #Internal medicine #Medicine #Odds ratio #Oncology #Regimen #Surgery

paper · doi:10.1038/s41416-022-01726-5

openalex publication_date 2022/02/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Cited by

• The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. [europepmc]
• Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes. [europepmc]
• Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. [europepmc]
• Clinical Significance of Intramural Metastasis as an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma. [europepmc]
• Mechanisms of esophageal cancer metastasis and treatment progress. [europepmc]
• Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis. [europepmc]
• Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. [europepmc]
• Two versus three to four cycles of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice. [europepmc]
• CD45RO-Positive Memory T-Cell Density in the Tumoral Core and Invasive Margin Predict Long-Term Survival in Esophageal Squamous Cell Carcinoma. [europepmc]
• Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma. [europepmc]
• Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable/recurrent esophageal squamous cell carcinoma. [europepmc]
• Initial reduction of the primary tumor or lymph nodes: which is the better prognostic factor in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemotherapy followed by surgery? [europepmc]
• Perioperative outcomes of esophagectomy after doublet versus docetaxel-based triplet neoadjuvant chemotherapy in older patients: A nationwide inpatient database study in Japan. [europepmc]
• Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel + cisplatin + 5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. [europepmc]
• Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma. [europepmc]
• Survival risk prediction nomogram for patients with resectable esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy followed by surgery: a retrospective study. [europepmc]